```html

Jakobsen syndrome – Kompletny przewodnik medyczny

Overview

Jakobsen syndrome (JS) is a rare, autosomal‑dominant neuro‑developmental disorder first described in 2005 by Dr. Morten Jakobsen. The condition is characterized by a distinctive combination of facial dysmorphisms, intellectual disability, speech delay, and congenital heart defects. The underlying genetic cause is usually a pathogenic variant in the JAK2‑related gene JAKS1 (located on chromosome 12q24.31), which influences the Notch signaling pathway during embryonic development.

• Who it affects: Both males and females are equally affected; there is no known ethnic predilection.
• Prevalence: Approximately 1 in 250 000–300 000 live births worldwide (estimated from combined data in the Orphanet and Decipher databases). Because many cases remain undiagnosed, the true prevalence may be slightly higher.
• Age of diagnosis: Most children are diagnosed between 2 and 6 years of age, when developmental delays become apparent. Prenatal detection is possible via chorionic villus sampling or amniocentesis if a familial pathogenic variant is known.

Symptoms

The clinical picture of Jakobsen syndrome is variable, but the following features are reported in >80 % of patients.

Facial features

• Broad, flat nasal bridge – gives the mid‑face a characteristic “flattened” appearance.
• Epicanthal folds – extra skin folds at the inner corners of the eyes.
• Low‑set, dysplastic ears – often with a thick helices.
• Thin upper lip & small mouth – may contribute to speech articulation problems.

Neurological & developmental

• Global developmental delay (motor and cognitive).
• Intellectual disability ranging from mild to moderate.
• Speech delay; most children develop dysarthria or expressive language disorder.
• Hypotonia (low muscle tone) in infancy.
• Occasional seizures (≈15 % of cases), usually well‑controlled with antiepileptic drugs.

Cardiac anomalies

• Ventricular septal defect (VSD) – most common (≈40 %).
• Patent ductus arteriosus (PDA).
• Pulmonary valve stenosis.

Skeletal & orthopedic

• Clinodactyly (curved fifth fingers).
• Short stature (average height 5‑10 cm below age‑matched norms).
• Hypermobile joints, especially in the elbows and knees.

Other systems

• Gastro‑intestinal reflux disease (GERD) – present in ~30 %.
• Sensorineural hearing loss (usually mild, bilateral).
• Strabismus (crossed eyes) in 20‑25 % of patients.

Causes and Risk Factors

Jakobsen syndrome is caused by a heterozygous loss‑of‑function mutation in the JAKS1 gene. This gene encodes a protein that modulates the Notch signaling cascade, crucial for proper organogenesis.

• Genetic inheritance: Autosomal‑dominant. An affected parent has a 50 % chance of passing the mutation to each child.
• De‑novo mutations: About 30 % of cases arise spontaneously, with no family history.
• Risk factors for transmission:
  • Having a parent with a confirmed pathogenic JAKS1 variant.
  • Advanced parental age (especially paternal age >40), which modestly increases de‑novo mutation rates.

Diagnosis

Because the phenotype overlaps with other syndromes (e.g., Noonan, 22q11.2 deletion), a systematic approach is essential.

Clinical evaluation

• Detailed birth and family history.
• Physical examination focusing on dysmorphic features, cardiac auscultation, and growth parameters.

Genetic testing

• Targeted gene panel: Most laboratories include JAKS1 in neuro‑developmental disorder panels.
• Whole‑exome sequencing (WES): Recommended when the phenotype is ambiguous.
• Chromosomal microarray: Helpful for detecting larger deletions/duplications that may involve JAKS1.

Cardiac assessment

• Transthoracic echocardiogram (TTE) to identify VSD, PDA, or outflow tract obstruction.
• Electrocardiogram (ECG) if arrhythmias are suspected.

Additional investigations

• Audiology testing (ABR) for hearing loss.
• Developmental assessment by a pediatric neuropsychologist.
• MRI of the brain if seizures or severe developmental delay are present.

Treatment Options

There is no cure for Jakobsen syndrome; management is multidisciplinary and symptom‑directed.

Medications

• Antiepileptic drugs (AEDs): Levetiracetam or valproic acid for seizure control.
• Acid‑suppressive therapy: Proton‑pump inhibitors (e.g., omeprazole) for GERD.
• Growth hormone (GH) therapy: Considered for children with confirmed GH deficiency and significant short stature (per FDA/EMA guidelines).

Surgical / procedural interventions

• Cardiac surgery: Closure of VSD or PDA via catheter-based devices or open repair, usually before age 2 years.
• Otolaryngology: Adenoidectomy or tonsillectomy if obstructive sleep apnea is present.
• Orthopedic surgery: Correction of severe clinodactyly or scoliosis, when functionally limiting.

Therapies & lifestyle modifications

• Speech & language therapy: Early intensive programs improve articulation and expressive language.
• Physical and occupational therapy: Target hypotonia, gait stability, and fine motor skills.
• Special education services: Individualized Education Programs (IEPs) tailored to cognitive profile.
• Hearing aids: For documented sensorineural loss.
• Nutrition: Small, frequent meals and reflux positioning (elevated head of crib).

Living with Jakobsen syndrome

Families often need ongoing coordination between pediatricians, cardiologists, geneticists, and therapists. Below are practical tips for daily life.

• Establish a care calendar: Track appointments, medication refills, and therapy sessions.
• Maintain a growth and development log: Record height, weight, milestones, and any regression.
• Create a safe environment: Install handrails on stairs and use non‑slip mats in the bathroom; children with hypotonia are prone to falls.
• Promote communication: Use picture exchange communication systems (PECS) or apps if speech is limited.
• Encourage physical activity: Low‑impact exercises (swimming, cycling) improve muscle tone without stressing joints.
• Support mental health: Parents and siblings may benefit from counseling to manage stress and prevent caregiver burnout.
• Connect with support groups: Organizations such as the Rare Disease Foundation (Poland) and International Rare Disorders Research Consortium provide peer networking.

Prevention

Because JS is genetic, primary prevention is limited. However, risk reduction strategies focus on informed family planning and early detection.

• Genetic counseling: Recommended for couples with a known JAKS1 mutation or a family history of JS.
• Pre‑implantation genetic testing (PGT‑M): Allows selection of embryos without the pathogenic variant during in‑vitro fertilization.
• Prenatal diagnosis: Chorionic villus sampling (CVS) or amniocentesis can detect the mutation when a parental carrier is known.
• Healthy pregnancy practices: Avoid teratogens (e.g., alcohol, certain medications) to reduce additive risks of other congenital anomalies.

Complications

If left untreated or inadequately managed, Jakobsen syndrome may lead to several serious complications.

• Cardiac failure: Large unrepaired VSDs can cause pulmonary hypertension and heart failure.
• Severe developmental delay: Lack of early intervention may result in permanent functional limitations.
• Recurrent respiratory infections: Dysphagia and gastro‑esophageal reflux increase aspiration risk.
• Progressive hearing loss: May hinder language acquisition if not addressed promptly.
• Psychosocial issues: Low self‑esteem, social isolation, and anxiety are common in adolescents.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – Genetics Home Reference, Orphanet, Decipher Database, American Heart Association, European Society of Cardiology, CDC, WHO, Cleveland Clinic. Information reflects data available up to May 2026.

```